Nosis, a platform supporting substance use disorder (SUD) recovery, is launching from stealth in all 50 states.
The virtual startup leverages labs with health coaches and dietitians to address the biological and metabolic health needs of individuals in recovery. Its central thesis is that recovery must address both the mind and the body. Nosis does not provide therapy or medications for opioid use disorder, nor does it replace existing primary or specialty care teams.
“We have the data to show that lifestyle interventions are the biggest needle-mover in terms of chronic disease,” Duffy Fallon, founder and CEO of Nosis, told Fierce Healthcare.
Nosis’ two core offerings are Nosis Blueprint—an AI-driven assessment—and Nosis Core, the foundational 12-week program. The biological health assessment looks at over 85 biomarkers alongside health history, symptoms and more. Based on those results and a review with Nosis’ team, the core program then focuses on nutrition, movement, sleep, stress, supplementation, metabolic health and behavior change.
Members work with health coaches and registered dietitians, then transitioning to ongoing support and less frequent labs. They also participate in group sessions. Likely in early 2027, Nosis plans to roll out GLP-1s for weight management and off-label to manage substance cravings.
People with SUD often experience comorbid conditions. Issues like poor sleep, inflammation, metabolic dysfunction, hormonal imbalance and nutritional deficiencies affect how well someone feels on their path to recovery and can intensify cravings, Fallon argues. Yet, traditional SUD treatment rarely addresses these holistically.
The term Nosis comes from “gnosis,” a Greek word for knowledge in the inner-knowing sense. The idea is that once you figure out your body and mind, you start to know yourself. Fallon, in recovery himself, experienced this first-hand.
As he entered sobriety, Fallon was “just holding on by a thread,” he recalled, and couldn’t understand why. After working with a functional medicine provider, doing bloodwork, a gut microbiome test and personalized lifestyle interventions, Fallon finally had insight into his body.
“It was like—okay, I’m not crazy. There are real biochemical things happening that help explain why I feel this way. And it gave me a lot of motivation to change because I could actually see it. It wasn’t abstract anymore,” he said.
Earlier this year, Nosis participated in a 10-week accelerator through One Mind. It was also testing a different type of care model in an initial pilot of 30 members in Utah, providing comprehensive SUD care. Maintaining this would have made scaling to every state a challenge, and Nosis also found many of its members already had existing therapists and SUD providers. The biggest value the company was bringing to its members was, in fact, health coaching.
“There’s a lot of medical support out there, and medical support is extremely important,” Fallon acknowledged. “Our goal is not to necessarily throw more medication or medical providers at the problem, but really it’s to empower people in their own lives.”
All Nosis health coaches are themselves in recovery and national board-certified. Members get unlimited access to health coaching, including one-on-one video visits. Members also get unlimited messaging with their dietitian. The Nosis team can escalate higher-acuity issues as they arise. A psychiatric nurse practitioner, also board-certified as an addiction registered nurse, reviews Nosis’ program plans and escalation processes for clinical safety. Nosis’ head of care, a licensed clinical social worker in recovery, leads training and program development and coordinates care. On Nosis’ advisory board is a Stanford Medicine integrative medicine specialist, who advises the startup on its scientific framework.
“Recovery is about much more than the absence of substance use,” Patrick J. Kennedy, also on Nosis’ advisory board and co-founder of One Mind, said in a Nosis announcement. “It is about helping people improve their health, regain their ability to function, reconnect with their lives, and reach their potential. Nosis is bringing needed attention to physical health as an important and often overlooked part of that process.”
Though Nosis is enabled by AI, helping its team personalize recommendations, it still prioritizes the human relationship, particularly because people in recovery want to connect with a provider with lived experience, Fallon says. “The human element cannot be overstated,” Fallon noted.
Longer term, Nosis hopes to map how an individual responds to care over time, given their specific circumstances. This can then help drive understanding of which interventions, and when, support patients to drive a more precise recovery care model. Fallon compares this type of tailoring to precision oncology.
Nosis, which has raised a pre-seed round, operates a cash-pay subscription model, though it hopes to pursue payer reimbursement, eventually. Its pricing is $599 for Blueprint and $3,000 for Core, though special launch pricing pegs these at $499 and $2,500, respectively. Then there will be a monthly ongoing cost of $299, with continued access to the team and labs every six months.